Diabetes & Endocrinology
Latest news
532 articles · 20 / page
Tirzepatide Influences Muscle Composition Favorably Amid Weight Loss in Type 2 Diabetes: Insights from SURPASS-3 MRI Substudy
In type 2 diabetes patients, tirzepatide treatment led to significant reductions in muscle fat infiltration and adaptive decreases in muscle volume over 52 weeks, suggesting beneficial effects on muscle health concurrent with weight loss.
Henagliflozin and Aging Biomarkers in Type 2 Diabetes: A Groundbreaking Multicenter Trial Reveals Promising Anti-Aging Effects
A randomized placebo-controlled trial demonstrates that henagliflozin improves telomere length and multiple aging biomarkers in patients with type 2 diabetes, suggesting potential anti-aging benefits beyond glucose control.
Fulmetibant’s Role in Diabetic Neuropathic Pain: Insights from the Phase 2a BRADiNP Study
The BRADiNP study found that fulmetibant, a bradykinin-1 receptor antagonist, failed to significantly reduce diabetic neuropathic pain compared to placebo, despite favorable safety profiles, highlighting challenges in translating preclinica
Lobeglitazone as an Effective and Safe Addition to Metformin and Sitagliptin Therapy in Type 2 Diabetes: Results from a 52-Week Multicentre Phase III Trial
This phase III trial showed that adding lobeglitazone to metformin and sitagliptin significantly improves glycaemic control and insulin sensitivity with favorable safety over 52 weeks in Korean patients with type 2 diabetes inadequately con
Navigating the 2025 Best Diets: Tailored Eating Plans for Weight Loss, Hypertension, Menopause, and More
The 2025 Best Diets ranking identifies optimal eating plans tailored to specific health needs, such as weight loss, high blood pressure, menopause, and digestive health, emphasizing scientifically backed, sustainable dietary patterns.
Neutrophil Counts and Type 2 Diabetes Remission: Long-Term Benefits of Mediterranean Diet in Coronary Heart Disease Patients from the CORDIOPREV Study
Lower neutrophil counts predict greater type 2 diabetes remission with a Mediterranean diet in coronary heart disease patients, highlighting immune involvement in metabolic improvement over 5 years.
Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial
The SUMMIT trial reveals that tirzepatide improves heart failure outcomes and quality of life in obese HFpEF patients with or without type 2 diabetes, despite attenuated weight loss in diabetic patients.
Oral Lamivudine: A Promising Alternative in the Management of Diabetic Macular Edema
A recent randomized, double-blind trial demonstrates that oral lamivudine significantly improves visual acuity in patients with center-involved diabetic macular edema, offering a cost-effective and safer alternative to conventional anti-VEG
Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management
Orforglipron demonstrates significant glycemic control and weight reduction benefits in early type 2 diabetes and obesity, with favorable safety and oral administration convenience.
Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults
Oral semaglutide 25 mg once daily significantly reduces body weight versus placebo and improves physical function in adults with overweight or obesity, offering an alternative to injectable formulations.
Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study
A 12-week prospective study demonstrates tirzepatide significantly improves insulin sensitivity in obese Japanese patients with type 2 diabetes, independent of weight loss, as assessed by hyperinsulinaemic-euglycaemic clamp.
Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context
Ecnoglutide, a novel cAMP-biased GLP-1 receptor agonist, demonstrated non-inferior glycemic control and comparable safety to dulaglutide at 52 weeks in type 2 diabetes patients on metformin, offering a promising new treatment option.
Optimizing Metabolic and Physical Health in Obese Older Adults: Impact of Exercise Modalities on Insulin Secretion, CNTF, and IGF-1 During Weight Loss
Combining aerobic and resistance exercise with diet-induced weight loss in obese older adults significantly improves insulin secretion, preserves CNTFRα levels, and increases IGF-1, enhancing metabolic and physical function.
Hydroxytyrosol Supplementation Enhances Antioxidant and Anti-Inflammatory Status in Overweight Prediabetic Adults: Insights from a Randomized Controlled Trial
A 16-week randomized trial demonstrates that daily hydroxytyrosol supplementation significantly reduces oxidative stress and inflammatory markers in overweight individuals with prediabetes, highlighting its potential in preventing aging-rel
Enhancing Cognitive Function in Older Adults with Type 2 Diabetes: The Superior Effects of Tai Chi in a Mobile Health Trial
This randomized controlled trial demonstrates that Tai Chi, combined with wearable device monitoring in a telemedicine model, significantly improves cognitive function and sleep quality in older adults with type 2 diabetes, outperforming fi
Tai Chi and Cognitive Enhancement in Older Adults With Type 2 Diabetes Mellitus: Evidence From Randomized Controlled Trials Using Wearable Technology in mHealth Models
Emerging RCT evidence supports Tai Chi’s superior benefits over fitness walking in improving cognitive function and sleep quality among older adults with type 2 diabetes and mild cognitive impairment, facilitated by telemedicine and wearabl
Synergistic Effects of Combined Aerobic and Resistance Exercise with Diet on Insulin Secretion and Neurotrophic Factors in Older Adults with Obesity
Combining aerobic and resistance exercise with diet-induced weight loss in older adults with obesity significantly improves insulin secretion, metabolic health, and physical function, likely mediated by ciliary neurotrophic factor receptor
Amycretin: A Promising First-in-Class Dual GLP-1 and Amylin Receptor Agonist for Overweight and Obesity
Amycretin, a novel dual GLP-1 and amylin receptor agonist, demonstrated safety, tolerability, and dose-proportional pharmacokinetics in adults with overweight or obesity, supporting further trials on its weight loss efficacy.
Enhancing Metformin Efficacy and Tolerability in Prediabetes Through a Fermentable Carbohydrate-Rich Diet
A fermentable carbohydrate-enriched diet combined with metformin improves postprandial glycaemia, enhances GLP-1 secretion, and positively alters gut microbiota in prediabetic individuals, offering a personalized nutrition-pharmacology stra
Unlocking Precision Nutrition: Genetic Insights from the MIND Diet Trial for Cognitive Health
This article explores the genetic data resource from the MIND trial, highlighting its potential to tailor dietary interventions to mitigate cognitive decline and advance precision nutrition for Alzheimer’s risk populations.
Browse by specialty
Open language-specific specialty feeds and department pages.